Topical Glycopyrronium Tosylate (DRM04) for the Treatment of Primary Axillary Hyperhidrosis: Pooled Results from the ATMOS-1 and ATMOS-2 Phase 3 Randomized Controlled Trials

David M. Parisi,1 Adele A. Hieber,2 Alexander Nas,3 William P. Werschler,4 Lawrence Green,5 Richard D. Mamelok,5 John Quintero,6 Janice Drew,7 Dee Anna Glaser8

1Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA; 2The UTHealth McGovern Medical School-Houston, Houston, TX, 3Chariti – Universitaetsmedizin Berlin, Berlin, Germany; 4Premier Clinical Research, Spokane, WA; 5George Washington University School of Medicine, Washington, DC; 6Mamelok Consulting, Palo Alto, CA; 7Quest Diagnostics, MD, Oregon, Inc., Markle Park, CA; 8Stanford University, Stanford, CA

INTRODUCTION

• Hyperhidrosis affects an estimated 6–9% of the US population, or approximately 15.3 million people.1
• Axillary hyperhidrosis, which affects approximately 5–15% of the population with the condition,2 is more frequent than perceived.
• The impact of hyperhidrosis on quality of life, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-deficit/hyperactivity disorder5 is comparable to, or greater than, the impact of select diseases such as cystic fibrosis,3 asthma,4 and attention-definit...